Page 73 - JSOM Fall 2025

17. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibi- 37. Lasko MJ, Conelius A, Serrano O, Nicolau DP, Kuti JL. 1308. Ex
otic dosing in critically ill adult patients receiving continuous re- vivo impact of autologous blood transfusion (ABT) on concentra-
nal replacement therapy. Clin Infect Dis. 2005;41(8):1159–1166. tions of antibiotics used for surgical prophylaxis. Open Forum In-
doi:10.1086/444500 fect Dis. 2020;7(Suppl 1):S667. doi:10.1093/ofid/ofaa439.1490
18. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin meth- 38. Markantonis SL, Kostopanagiotou G, Panidis D, Smirniotis V,
anesulfonate and colistin in a critically ill patient receiving continu- Voros D. Effects of blood loss and fluid volume replacement
ous venovenous hemodiafiltration. Antimicrob Agents Chemother. on serum and tissue gentamicin concentrations during col-
2005;49(11):4814–4815. doi:10.1128/AAC.49.11.4814-4815 orectal surgery. Clin Ther. 2004;26(2):271–281. doi:10.1016/
19. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger s0149-2918(04)90025-2
G. Pharmacokinetics of meropenem in critically ill patients with 39. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does
acute renal failure undergoing continuous venovenous hemofil- intraoperative blood loss affect antibiotic serum and tissue con-
tration. Clin Pharmacol Ther. 1999;65(1):50–57. doi:10.1016/ centrations? Arch Surg. 1996;131(11):1165–1171. doi:10.1001/
S0009-9236(99)70121-9 archsurg.1996.01430230047009
20. Keller E, Böhler J, Busse-Grawitz A, Reetze-Bonorden P, Krumme 40. Fay KE, Yee L. Applying surgical antimicrobial standards in cesar-
B, Schollmeyer P. Single dose kinetics of piperacillin during con- ean deliveries. Am J Obstet Gynecol. 2018;218(4):416.e411–416.
tinuous arteriovenous hemodialysis in intensive care patients. e414. doi:10.1016/j.ajog.2018.01.016
Clin Nephrol. 1995;43(Suppl 1):S20–S23. 41. Burbank KM, Schauer SG, De Lorenzo RA, Wenke JC. Early ap-
21. Böhler J, Donauer J, Keller F. Pharmacokinetic principles during plication of topical antibiotic powder in open-fracture wounds:
continuous renal replacement therapy: drugs and dosage. Kidney a strategy to prevent biofilm formation and infections. OTA Int.
Int Suppl. 1999;(72):S24–S28. 2020;3(4):e091. doi:10.1097/OI9.0000000000000091
22. Arzuaga A, Maynar J, Gascón AR, et al. Influence of renal 42. Long A, Fillinger M, April MD, et al. Changes in emergency de-
function on the pharmacokinetics of piperacillin/tazobactam in partment volumes at the largest U.S. military hospital during the
intensive care unit patients during continuous venovenous hemo- COVID-19 pandemic. Mil Med. 2022;187(11–12):e1456–e1461.
filtration. J Clin Pharmacol. 2005;45(2):168–176. doi:10.1177/ doi:10.1093/milmed/usab322
0091270004269796 43. Braverman MA, Smith AA, Ciaraglia AV, et al. The regional whole
23. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Ade- blood program in San Antonio, TX: a 3-year update on prehos-
quacy of a vancomycin dosing regimen in patients receiving high- pital and in-hospital transfusion practices for traumatic and
flux hemodialysis. Am J Kidney Dis. 2005;46(4):681–687. doi: non-traumatic hemorrhage. Transfusion. 2022;62(Suppl 1):S80–
10.1053/j.ajkd.2005.07.018 S89. doi:10.1111/trf.16964
24. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance
during modeled continuous renal replacement therapy. Blood Pu- PMID: 40982578; DOI: 10.55460/9X33-ZRSV
rif. 2006;24(5–6):548–554. doi:10.1159/000097078
25. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing con-
cepts and recommendations for critically ill adult patients
receiving continuous renal replacement therapy or intermittent he-
modialysis. Pharmacotherapy. 2009;29(5):562–577. doi:10.1592/
phco.29.5.562
26. Klansuwan N, Ratanajamit C, Kasiwong S, Wangsiripaisan A.
Clearance of vancomycin during high-efficiency hemodialysis. J
Med Assoc Thai. 2006;89(7):986–991.
27. Ryan ML, Thorson CM, Otero CA, et al. Initial hematocrit in
trauma: a paradigm shift? J Trauma Acute Care Surg. 2012;72(1):
54–59; discussion 59–60. doi:10.1097/TA.0b013e31823d0f35
28. Bayliss G. Dialysis in the poisoned patient. Hemodial Int.
2010;14(2):158–167. doi:10.1111/j.1542-4758.2009.00427.x
29. Ibrahim RB, Liu C, Cronin SM, et al. Drug removal by plasma-
pheresis: an evidence-based review. Pharmacotherapy. 2007;27
(11):1529–1549. doi:10.1592/phco.27.11.1529
30. Bertino JS, Jr., Kliegman RM, Myers CM, Blumer JL. Alter-
ations in gentamicin pharmacokinetics during neonatal exchange
transfusion. Dev Pharmacol Ther. 1982;4(3–4):205–215. doi:10.
1159/000457409.
31. Keller F, Wagner K, Faber U, et al. Elimination kinetics of plasma
exchange. Klin Wochenschr. 1983;61(22):1115–1122. doi:10.
1007/BF01530838
32. Bakken JS, Cavalieri SJ, Gangeness D, Kubat T, Pollack JR. In-
fluence of therapeutic plasmapheresis on elimination of ceftiax-
one. Antimicrob Agents Chemother. 1993;37(5):1171–1173. doi:
10.1128/AAC.37.5.1171
33. Fauvelle F, Lortholary O, Tod M, et al. Pharmacokinetics of
ceftriaxone during plasma exchange in polyarteritis nodosa pa-
tients. Antimicrob Agents Chemother. 1994;38(7):1519–1522.
doi:10.1128/AAC.38.7.1519
34. Bakken JS, Cavalieri SJ, Gangeness D. Influence of plasma ex-
change pheresis on plasma elimination of ceftriaxone. Antimicrob
Agents Chemother. 1990;34(6):1276–1277. doi:10.1128/AAC.
34.6.1276
35. Samtleben W, Mistry-Burchardi N, Hartmann B, Lennertz A,
Bosch T. Therapeutic plasma exchange in the intensive care set-
ting. Ther Apher. 2001;5(5):351–357. doi:10.1046/j.1526-0968.
2001.00383.x
36. McClellan SD, Whitaker CH, Friedberg RC. Removal of vanco-
mycin during plasmapheresis. Ann Pharmacother. 1997;31(10):
1132–1136. doi:10.1177/106002809703101003

Antibiotic Concentrations after Massive Transfusion | 71